Search research articles
Contact Us
Filters
Showing results (311-320 of 351) with videos related to
Page
of 36
Sort By:
Journal of Chemical Information and Modeling
|
September 21, 2013
Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors
Xin Xue, Jin-Lian Wei, Li-Li Xu, et al.
Plos One
|
May 19, 2011
PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy
Jianbiao Zhou, Chonglei Bi, Wee-Joo Chng, et al.
Ebiomedicine
|
June 30, 2023
AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice
Choong Tat Keng, Thinesshwary Yogarajah, Regina Ching Hua Lee, et al.
Thoracic Cancer
|
October 16, 2019
Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
Shih-Hao Huang, Allen Chung-Cheng Huang, Chin-Chou Wang, et al.
European Journal of Medicinal Chemistry
|
December 31, 2024
Discovery of the salicylaldehyde-based compound DDO-02267 as a lysine-targeting covalent inhibitor of ALKBH5
Wen-Long Fei, Ying-Zhe Wang, Qing-Lan Feng, et al.
Therapeutic Advances in Medical Oncology
|
August 11, 2021
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
Allen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, et al.
Cancers
|
January 21, 2022
Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation
Chih-Hsi Scott Kuo, Tzu-Hsuan Chiu, Pi-Hung Tung, et al.
Scientific Reports
|
March 16, 2022
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis
Tzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, et al.
International Journal of Cancer
|
September 24, 2021
Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
Chi-Hsien Huang, Jia-Shiuan Ju, Tzu-Hsuan Chiu, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 25, 2025
CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages
Xutao Xu, Qianqian Wang, Ke Guo, et al.
Page
of 36
Search research articles
Search
Showing results (311-320 of 351) with videos related to
Sort By:
Page
of 36
Journal of Chemical Information and Modeling
|
September 21, 2013
Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors
Xin Xue, Jin-Lian Wei, Li-Li Xu, et al.
Plos One
|
May 19, 2011
PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy
Jianbiao Zhou, Chonglei Bi, Wee-Joo Chng, et al.
Ebiomedicine
|
June 30, 2023
AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice
Choong Tat Keng, Thinesshwary Yogarajah, Regina Ching Hua Lee, et al.
Thoracic Cancer
|
October 16, 2019
Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
Shih-Hao Huang, Allen Chung-Cheng Huang, Chin-Chou Wang, et al.
European Journal of Medicinal Chemistry
|
December 31, 2024
Discovery of the salicylaldehyde-based compound DDO-02267 as a lysine-targeting covalent inhibitor of ALKBH5
Wen-Long Fei, Ying-Zhe Wang, Qing-Lan Feng, et al.
Therapeutic Advances in Medical Oncology
|
August 11, 2021
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
Allen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, et al.
Cancers
|
January 21, 2022
Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation
Chih-Hsi Scott Kuo, Tzu-Hsuan Chiu, Pi-Hung Tung, et al.
Scientific Reports
|
March 16, 2022
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis
Tzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, et al.
International Journal of Cancer
|
September 24, 2021
Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
Chi-Hsien Huang, Jia-Shiuan Ju, Tzu-Hsuan Chiu, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 25, 2025
CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages
Xutao Xu, Qianqian Wang, Ke Guo, et al.
Page
of 36